| 704 |
Centers for Disease Control and Prevention |
Html |
en |
Notes from the Field: Severe Illness Associated withReported Use of Synthetic Marijuana - Colorado, August-September2013 |
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. |
| mmwrq@cdc.gov. | 0.549899 |
| medical charts | 0.545574 |
| patient visits | 0.57888 |
| Human Services | 0.568698 |
| assistive technology | 0.547386 |
| systolic blood pressure | 0.581258 |
| MMWR HTML versions | 0.572185 |
| U.S. Department | 0.567244 |
| public health departments | 0.584487 |
| synthetic marijuana product | 0.745389 |
| electronic PDF version | 0.572814 |
| probable cases | 0.655398 |
| Dead Man Walking | 0.574468 |
| intensive care unit | 0.57581 |
| synthetic marijuana intoxication | 0.685322 |
| Environmental Health | 0.549397 |
| patients | 0.587205 |
| Olaniyi Olayinka | 0.570373 |
| epidemiologic investigation | 0.547836 |
| Colorado Dept | 0.549602 |
| altered mental status | 0.668435 |
| Lauren S. Lewis | 0.568652 |
| CDC Experience Fellow | 0.579126 |
| original paper copy | 0.56949 |
|
| plant material | 0.547639 |
| illness onset | 0.58173 |
| Colorado EDs | 0.567662 |
| Colorado Department | 0.590197 |
| probable case | 0.560351 |
| standard laboratory tests | 0.575083 |
| original MMWR paper | 0.575264 |
| U.S. Government Printing | 0.573231 |
| Mike Van Dyke | 0.572527 |
| ED visits | 0.545558 |
| synthetic marijuana exposure | 0.683058 |
| adverse health effects | 0.582726 |
| certain geographic areas | 0.570744 |
| Denver metropolitan area | 0.57758 |
| public health | 0.625263 |
| various synthetic cannabinoids | 0.639914 |
| Colorado ED | 0.557403 |
| synthetic marijuana | 0.934516 |
| subject line | 0.548129 |
| Colorado Bureau | 0.57171 |
| synthetic marijuana products | 0.728851 |
| Colorado law enforcement | 0.588186 |
| similar outbreak | 0.55348 |
| ED visit reports | 0.579012 |
|
CLICK HERE |
| 971 |
Centers for Disease Control and Prevention |
Html |
en |
Likely Female-to-Female Sexual Transmission of HIV - Texas,2012 |
Shirley K. Chan, MPH1, Lupita R. Thornton1, Karen J. |
| newly acquired infection | 0.30326 |
| HIV-1 viral load | 0.488387 |
| injection drug | 0.312206 |
| HIV virus | 0.317247 |
| 6-month monogamous relationship | 0.433348 |
| identical HIV-1 drug | 0.311334 |
| HIV infections | 0.326552 |
| unprotected sexual contact | 0.319043 |
| HIV risk behavior | 0.380134 |
| sexual contact | 0.957582 |
| HIV status | 0.319193 |
| IDU | 0.320251 |
| risk factors | 0.349806 |
| female-to-female sexual transmission | 0.338632 |
| body fluids | 0.28731 |
| female-to-female sexual contact | 0.782203 |
| sexual contact history | 0.31465 |
| upper respiratory infection | 0.293367 |
| female-to-female transmission | 0.28761 |
| human immunodeficiency virus | 0.344245 |
| EIA serology screening | 0.353587 |
| female sex partner | 0.29795 |
| heterosexual sex | 0.364376 |
| women | 0.465972 |
| HIV-1 Western blot | 0.443371 |
|
| better health outcomes | 0.330719 |
| female sexual partner | 0.290964 |
| woman | 0.348915 |
| newly infected woman | 0.345039 |
| safer sex practices | 0.354093 |
| drug resistance mutations | 0.326353 |
| insertive sex toys | 0.28822 |
| antiretroviral treatment | 0.335494 |
| female partner | 0.282277 |
| CD4+ T-lymphocyte count | 0.335732 |
| HIV-1 polymerase | 0.278755 |
| IDU history | 0.298639 |
| HIV diagnosis | 0.336083 |
| newly diagnosed HIV | 0.385055 |
| female sexual partners | 0.302699 |
| HIV transmission | 0.672228 |
| 18,199 women with acquired | 0.289541 |
| medical care | 0.325544 |
| Western blot tests | 0.279653 |
| Western blot test | 0.279082 |
| HIV | 0.750119 |
| sex toys | 0.290024 |
| HIV viral load | 0.34965 |
| WSW | 0.31606 |
|
CLICK HERE |
| 4617 |
Centers for Disease Control and Prevention |
Html |
en |
People with Special Needs|Earthquakes |
Information on terrorism and public health. Provided by the Centers for Disease Control and Prevention (CDC). |
| battery-operated TV | 0.770557 |
| natural disasters | 0.731636 |
| co-worker | 0.546659 |
| danger | 0.5445 |
| spouse | 0.555904 |
| fears | 0.546528 |
| corner | 0.543233 |
| children | 0.617837 |
| medications | 0.545719 |
| friend | 0.543349 |
| case | 0.546592 |
| limitations | 0.552883 |
| community religious organization | 0.910454 |
| aloud books | 0.738283 |
| mental health services | 0.908953 |
| normal reaction | 0.745456 |
| sturdy table | 0.766903 |
| school counselor | 0.726419 |
| earthquake | 0.723956 |
| doorway | 0.555148 |
| list | 0.596653 |
| fireplaces | 0.546122 |
| recurrence | 0.551269 |
| anxiety | 0.639675 |
| specific needs | 0.776342 |
|
| spare key | 0.752277 |
| disrupts daily activities | 0.928927 |
| items | 0.545217 |
| yellow pages | 0.718827 |
| child | 0.70947 |
| imagined misdeeds | 0.745511 |
| wheelchair | 0.606508 |
| emergency information | 0.736316 |
| clean-up activities | 0.729439 |
| head | 0.543139 |
| professional assistance | 0.718843 |
| roommate | 0.563944 |
| prolonged fear | 0.789894 |
| wallet | 0.561505 |
| capabilities | 0.547452 |
| outer walls | 0.742422 |
| neighbor | 0.558709 |
| telephone directory | 0.723124 |
| home | 0.544205 |
| punishment | 0.545604 |
| physical reassurance | 0.74653 |
| location | 0.544191 |
| family | 0.583848 |
| purse | 0.559381 |
|
CLICK HERE |
| 5950 |
Centers for Disease Control and Prevention |
Html |
en |
Ethylene dibromide - NIOSH Pocket Guide to Chemical Hazards |
null |
| MPEG | 0.378858 |
| search | 0.263099 |
| PDF | 0.261307 |
| PPT | 0.446092 |
|
| DOC | 0.368812 |
| information | 0.262482 |
| different file formats | 0.938484 |
| page | 0.276773 |
|
CLICK HERE |
| 6757 |
Centers for Disease Control and Prevention |
Html |
en |
Global Health - South Africa - CDC's HIV Prevention Programs: Biomedical Prevention |
CDC partners in South Africa with government and parastatal agencies, private institutions, universities and non-governmental organizations to improve the country’s public health foundation, to prevent transmission of HIV, to provide care and treatment for those who are already infected with HIV, and to strengthen laboratory capacity.
|
| tide | 0.333482 |
| South African Government | 0.923719 |
| country | 0.36178 |
| new HIV infections | 0.645798 |
| passage | 0.332258 |
| population-level reduction | 0.486855 |
| age bracket | 0.459687 |
| percent | 0.337028 |
| youth | 0.33016 |
| traditional rite | 0.456505 |
| Department | 0.334604 |
| MMCs | 0.362045 |
| service delivery | 0.45841 |
| planned MMC sites | 0.60946 |
| HSRC report | 0.481828 |
| ethnic groups | 0.464771 |
|
| percentage | 0.334994 |
| majority | 0.370868 |
| VMMC increases | 0.451924 |
| HIV-negative men | 0.466837 |
| high HIV incidence | 0.590654 |
| male circumcision | 0.893942 |
| PEPFAR | 0.365165 |
| eligible males | 0.531698 |
| USAID | 0.347775 |
| Defense | 0.334575 |
| vision | 0.334361 |
| low existing rates | 0.569348 |
| traditional circumcision | 0.687938 |
| medical male circumcision | 0.747025 |
| targeted locations | 0.457218 |
|
CLICK HERE |
| 7576 |
Centers for Disease Control and Prevention |
Html |
en |
Severe Respiratory Illness Associated with a Novel Coronavirus - Saudi Arabia and Qatar, 2012 |
CDC is working closely with the World Health Organization (WHO) and other partners to better understand the public health risk presented by a recently detected, novel coronavirus. This virus has been identified in two patients, both previously healthy adults who suffered severe respiratory illness (1,2). The first patient, a man aged 60 years from Saudi Arabia, was hospitalized in June 2012 and died; the second patient, a man aged 49 years from Qatar with onset of symptoms in September 2012 was transported to the United Kingdom for intensive care. |
| case investigation | 0.330292 |
| Human Services | 0.39259 |
| available diagnostic tests | 0.395856 |
| U.S. Department | 0.389292 |
| MMWR HTML versions | 0.379755 |
| CDC Emergency Operations | 0.470365 |
| electronic PDF version | 0.382616 |
| novel coronavirus | 0.844363 |
| CDC coronavirus website | 0.827128 |
| public health risk | 0.447269 |
| World Health Organization | 0.445765 |
| personal protective equipment | 0.384466 |
| Contact GPO | 0.309607 |
| animal species | 0.310584 |
| Euro Surveill | 0.485263 |
| lower respiratory illness | 0.49139 |
| life support | 0.319364 |
| severe respiratory disease | 0.475862 |
| case definition | 0.506763 |
| original paper copy | 0.375157 |
| Kingdom public health | 0.403059 |
| renal failure | 0.31189 |
| wide range | 0.310172 |
| common cold | 0.310021 |
|
| healthy adults | 0.31424 |
| probable case | 0.336566 |
| respiratory illness | 0.942623 |
| original MMWR paper | 0.387221 |
| U.S. Government Printing | 0.38651 |
| Saudi Arabia | 0.550604 |
| M. Novel coronavirus | 0.554063 |
| acute respiratory syndrome | 0.482718 |
| viral genetic sequences | 0.391869 |
| local health departments | 0.569204 |
| public health | 0.516166 |
| ECDC Internal Response | 0.386253 |
| travel history | 0.314441 |
| U.S. residents | 0.312481 |
| acute respiratory illness | 0.675503 |
| Interim case definitions | 0.420619 |
| intensive care | 0.314145 |
| United Kingdom | 0.52246 |
| public health measures | 0.401995 |
| new virus | 0.399856 |
| health-care–associated transmission | 0.313181 |
| severe respiratory illness | 0.693816 |
| Genetic sequence data | 0.39612 |
| et al | 0.392228 |
|
CLICK HERE |
| 11613 |
Centers for Disease Control and Prevention |
Html |
en |
Flu Season is Around the Corner | Features | CDC |
Everyone 6 months and older should get an annual flu vaccine. It takes about two weeks after vaccination for your body to develop full protection against the flu. Get vaccinated to protect yourself and your loved ones! |
| CDC | 0.264078 |
| American Medical Association | 0.258379 |
| 2017-2018 flu season | 0.455073 |
| injectable influenza vaccines | 0.303556 |
| possible serious complications | 0.237653 |
| CDC experts | 0.241757 |
| best way | 0.237577 |
| HealthMap Vaccine Finder | 0.293282 |
| sure bet | 0.237352 |
| flu vaccines | 0.522048 |
| flu vaccination | 0.629451 |
| influenza-associated medical visits | 0.301301 |
| vaccination rates | 0.251516 |
| increased risk | 0.234898 |
| percentage point increase | 0.257924 |
| chronic medical conditions | 0.262937 |
| flu complication | 0.461869 |
| flu illness | 0.574243 |
| 2015-2016 influenza season | 0.287524 |
| recombinant influenza vaccines | 0.30285 |
| wide range | 0.235741 |
| influenza illnesses | 0.277699 |
| extreme inflammatory response | 0.261513 |
| United States | 0.26925 |
|
| professional medical groups | 0.258429 |
| flu vaccine | 0.73908 |
| flu virus | 0.514528 |
| flu complications | 0.496352 |
| flu virus infection | 0.489527 |
| spray flu vaccine | 0.491978 |
| health care | 0.253886 |
| higher risk | 0.237736 |
| moderate complications | 0.238311 |
| influenza vaccines | 0.318171 |
| flu seasons | 0.463571 |
| locations offering flu | 0.454701 |
| tool modern medicine | 0.260518 |
| annual influenza vaccine | 0.321391 |
| influenza vaccination | 0.278558 |
| people | 0.276445 |
| flu | 0.915519 |
| flu shot | 0.548508 |
| illness milder | 0.237675 |
| influenza viruses | 0.257965 |
| available flu vaccines | 0.472438 |
| flu season | 0.497477 |
| influenza-associated hospitalizations | 0.264762 |
| risk | 0.242014 |
|
CLICK HERE |
| 12005 |
Centers for Disease Control and Prevention |
Html |
en |
CDC Statement on LAIV Effectiveness and Vaccination of Children |
CDC Statement on LAIV Effectiveness and Vaccination of Children - CDC |
| influenza | 0.911448 |
| season data | 0.204782 |
| U.S. Influenza Vaccine | 0.563914 |
| CDC | 0.300616 |
| Mortality Weekly Report | 0.376135 |
| season LAIV | 0.205436 |
| interim published estimates | 0.260041 |
| subtyped viruses | 0.270907 |
| influenza A viruses | 0.432862 |
| 2014-2015 influenza season | 0.415186 |
| flu vaccine | 0.333943 |
| H1N1 vaccine virus | 0.362577 |
| HealthMap Vaccine Finder | 0.335673 |
| Vaccine uptake data | 0.34159 |
| different influenza viruses | 0.486487 |
| Hemisphere influenza vaccine | 0.485433 |
| Influenza H1N1 | 0.339471 |
| vaccine virus | 0.414478 |
| current influenza vaccination | 0.35589 |
| influenza virus infection | 0.392136 |
| children | 0.270632 |
|
| influenza B viruses | 0.610093 |
| season | 0.471746 |
| seasonal surveillance data | 0.224818 |
| Vaccine providers | 0.276879 |
| Flu VE Network | 0.248055 |
| licensed age-appropriate vaccine | 0.366916 |
| specific vaccine preparation | 0.324775 |
| 2014-2015 season | 0.230412 |
| antigenic variant virus | 0.222413 |
| influenza vaccine | 0.805754 |
| 2014-2015 influenza vaccine | 0.492363 |
| antigenically drifted viruses | 0.432168 |
| H3N2 viruses | 0.280533 |
| influenza vaccination | 0.36146 |
| nasal spray vaccine | 0.381987 |
| H1N1 viruses | 0.363776 |
| inactivated influenza vaccine | 0.556986 |
| U.S. market | 0.215854 |
| influenza viruses | 0.496518 |
| Influenza Update | 0.317021 |
| better protection | 0.22297 |
|
CLICK HERE |
| 12011 |
Centers for Disease Control and Prevention |
Html |
en |
Guidance for Screening and Caring for Pregnant Women with Ebola Virus Disease for Healthcare Providers in U.S. Hospitals |
null |
| longest known incubation | 0.396954 |
| CDC guidance | 0.401197 |
| uncertain control measures | 0.653015 |
| pregnant patient | 0.423439 |
| screen patients | 0.419239 |
| recent travel | 0.433082 |
| similar risk factors | 0.393254 |
| fetal loss | 0.4045 |
| Ebola virus exposure | 0.528524 |
| routine obstetric care | 0.407015 |
| public health authorities | 0.39322 |
| Ebola virus | 0.872775 |
| neonatal survivals.1 Causes | 0.394222 |
| pregnant women | 0.970746 |
| pregnant puis | 0.504356 |
| direct contact | 0.395077 |
| pregnant woman | 0.428636 |
| spontaneous fetal loss | 0.389189 |
| large amounts | 0.401253 |
| transplacental viral passage | 0.389081 |
| pregnant healthcare workers | 0.530265 |
| confirmed EVD.7 Training | 0.401928 |
| U.S. healthcare providers | 0.416689 |
| healthcare team caring | 0.402533 |
| risk factors | 0.468348 |
|
| complications.10 Healthcare providers | 0.410399 |
| personal protective equipment | 0.481516 |
| patients | 0.510959 |
| epidemiologic risk factors | 0.464457 |
| body fluids | 0.39993 |
| EVD | 0.679989 |
| state health department.6 | 0.396346 |
| highly developed healthcare | 0.402489 |
| clinically stable persons | 0.393252 |
| Ebola virus disease | 0.55567 |
| healthcare providers | 0.545541 |
| PPE | 0.412624 |
| U.S. hospitals | 0.459031 |
| urban settings | 0.488827 |
| healthcare worker exposure | 0.405421 |
| overall physical condition | 0.387206 |
| perinatal mortality rates | 0.393274 |
| early gestational ages | 0.388771 |
| Asymptomatic pregnant women | 0.490026 |
| confirmed EVD | 0.486506 |
| widespread Ebola transmission | 0.738724 |
| small case series | 0.39228 |
| healthcare workers | 0.769491 |
| general medical management | 0.393226 |
|
CLICK HERE |
| 12369 |
Centers for Disease Control and Prevention |
Image |
null |
Prostate Cancer: Take Time to Decide (600W x 1310H) |
null |
|
|
CLICK HERE |